|
Item 3.01
|
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
|
On September 4, 2018, Edge Therapeutics, Inc. (“Edge”) received written notice from the staff (the “Staff”) of the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that Edge was not in compliance with Nasdaq Listing Rule 5450(a)(1) because the bid price for Edge’s common stock had closed below $1.00 per share for the previous 30 consecutive business days. The notification of noncompliance has no immediate effect on the listing or trading of Edge’s common stock on the Nasdaq Global Select Market under the symbol “EDGE,” and Edge is currently evaluating its alternatives to regain compliance with this rule.
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), Edge has 180 calendar days from the date of such notice, or until March 4, 2019, to regain compliance with the minimum bid price requirement,
unless the Staff exercises its discretion to extend this 10 business day period pursuant to Nasdaq Listing Rule 5810(c)(3)(F). If Edge regains compliance, Nasdaq will provide Edge with written confirmation and will close the matter.
To regain compliance, the bid price for Edge’s common stock must close at $1.00 per share or more for a minimum of 10 consecutive business days.
If Edge does not regain compliance with Rule 5450(a)(1) by March 4, 2019, Edge may be eligible for an additional 180 calendar day compliance period. To qualify, Edge would need to transfer the listing of its common stock to The Nasdaq Capital Market, provided that it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market except for the bid price requirement, and will need to provide written notice of its intention to cure its deficiency during the second compliance period. If it meets these criteria, the Staff will notify Edge that it has been granted an additional 180 calendar day compliance period. However, if it appears to the Staff that Edge will not be able to cure the deficiency, or if Edge is otherwise not eligible, Nasdaq would notify Edge that its securities would be subject to delisting. In the event of such a notification, Edge may appeal the Staff’s determination to delist its securities, but there can be no assurance the Staff would grant Edge’s request for continued listing.
Except for the factual statements made herein, information contained in this report consists of “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, without limitation, statements with respect to Edge’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “seeks,” “intends,” “plans,” “potential” or similar expressions, including statements with respect to the potential effects of its products and plans to assess and undertake next steps for Edge. These statements are based upon the current beliefs and expectations of Edge’s management and are subject to significant risks and uncertainties. Actual results may differ significantly from those set forth in the forward-looking statements.
The forward-looking statements contained in this report speak only as of the date of this report and Edge undertakes no obligation to publicly update any forward-looking statements to reflect changes in information, events or circumstances after the date of this report, unless required by law.